Zhican Wang

Revolution Medicines (United States) — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

24h-index2.1kcitations122works4.12yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer, Hypoxia, and Metabolism(65), Cancer Research and Treatments(62), ATP Synthase and ATPases Research(29), Mechanisms of cancer metastasis(23), Vitamin D Research Studies(14)

Publications122 total

Abrogation of Oncogenic RAS Signaling by a RAS(ON) Inhibitor Doublet Primes Immune-refractory KRAS G12C-mutant NSCLC for Immune Checkpoint Blockade
Cancer Discovery·2026Open Access
Supplementary Tables1 from The Bi-steric, mTORC1-Selective Inhibitor, RMC-5552, in Advanced Solid Tumors: A Phase 1 Trial
2025Open Access
Suppl Figures 1 from The Bi-steric, mTORC1-Selective Inhibitor, RMC-5552, in Advanced Solid Tumors: A Phase 1 Trial
2025Open Access
The Bi-steric, mTORC1-Selective Inhibitor, RMC-5552, in Advanced Solid Tumors: A Phase 1 Trial
Clinical Cancer Research·2025· 2 citedOpen Access
Correction: Translational and Therapeutic Evaluation of RAS-GTP Inhibition by RMC-6236 in RAS-Driven Cancers
Cancer Discovery·2025Open Access
Supplementary Table S5 from Translational and Therapeutic Evaluation of RAS-GTP Inhibition by RMC-6236 in RAS-Driven Cancers
2025Open Access
Supplementary Table S8 from Translational and Therapeutic Evaluation of RAS-GTP Inhibition by RMC-6236 in RAS-Driven Cancers
2025Open Access
Supplementary Table S6 from Translational and Therapeutic Evaluation of RAS-GTP Inhibition by RMC-6236 in RAS-Driven Cancers
2025Open Access
Figure 4 from Translational and Therapeutic Evaluation of RAS-GTP Inhibition by RMC-6236 in RAS-Driven Cancers
2025Open Access
Supplementary Table S4 from Translational and Therapeutic Evaluation of RAS-GTP Inhibition by RMC-6236 in RAS-Driven Cancers
2025Open Access
Figure 3 from Translational and Therapeutic Evaluation of RAS-GTP Inhibition by RMC-6236 in RAS-Driven Cancers
2025Open Access
Figure 6 from Translational and Therapeutic Evaluation of RAS-GTP Inhibition by RMC-6236 in RAS-Driven Cancers
2025Open Access
Supplementary Method from Translational and Therapeutic Evaluation of RAS-GTP Inhibition by RMC-6236 in RAS-Driven Cancers
2025Open Access
Figure 5 from Translational and Therapeutic Evaluation of RAS-GTP Inhibition by RMC-6236 in RAS-Driven Cancers
2025Open Access
Figure 7 from Translational and Therapeutic Evaluation of RAS-GTP Inhibition by RMC-6236 in RAS-Driven Cancers
2025Open Access
Figure 2 from Translational and Therapeutic Evaluation of RAS-GTP Inhibition by RMC-6236 in RAS-Driven Cancers
2025Open Access
Figure 1 from Translational and Therapeutic Evaluation of RAS-GTP Inhibition by RMC-6236 in RAS-Driven Cancers
2025Open Access
Supplementary Table S7 from Translational and Therapeutic Evaluation of RAS-GTP Inhibition by RMC-6236 in RAS-Driven Cancers
2025Open Access
Supplementary Table S3 from Translational and Therapeutic Evaluation of RAS-GTP Inhibition by RMC-6236 in RAS-Driven Cancers
2025Open Access
Supplementary Table S1 from Translational and Therapeutic Evaluation of RAS-GTP Inhibition by RMC-6236 in RAS-Driven Cancers
2025Open Access
page 1 of 7Next →

Frequent Co-authors

Mallika Singh(24), Jacqueline A.M. Smith(23), Adrian L. Gill(21), David Wildes(19), John E. Knox(18), Elena S. Koltun(17), Kenneth E. Thummel(16), Kyle J. Seamon(14), Abby Marquez(14), Aidan C.A. Tomlinson(13), Bianca J. Lee(12), Zhengping Wang(11), Jingjing Jiang(11), W. Clay Gustafson(10), Yu Chi Yang(10), James Cregg(9), Lingyan Jiang(8), Matthew Holderfield(8), Marie Ménard(8), Stephanie Chang(8)